- Home
- SNN vs QGEN Comparison
SNN vs QGEN Comparison
Compare SNN & QGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SNN
- QGEN
- Stock Information
- Founded
- SNN 1856
- QGEN 1986
- Country
- SNN United Kingdom
- QGEN Netherlands
- Employees
- SNN N/A
- QGEN N/A
- Industry
- SNN Industrial Specialties
- QGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- SNN Health Care
- QGEN Health Care
- Exchange
- SNN Nasdaq
- QGEN Nasdaq
- Market Cap
- SNN 11.0B
- QGEN 9.5B
- IPO Year
- SNN 1999
- QGEN 1996
- Fundamental
- Price
- SNN $24.66
- QGEN $44.67
- Analyst Decision
- SNN Strong Buy
- QGEN Buy
- Analyst Count
- SNN 1
- QGEN 9
- Target Price
- SNN N/A
- QGEN $51.42
- AVG Volume (30 Days)
- SNN 740.3K
- QGEN 865.8K
- Earning Date
- SNN 08-01-2024
- QGEN 02-04-2025
- Dividend Yield
- SNN 3.04%
- QGEN 2.96%
- EPS Growth
- SNN 39.77
- QGEN N/A
- EPS
- SNN 0.35
- QGEN 0.41
- Revenue
- SNN $5,642,000,000.00
- QGEN $1,966,174,000.00
- Revenue This Year
- SNN $6.97
- QGEN $2.78
- Revenue Next Year
- SNN $5.46
- QGEN $5.69
- P/E Ratio
- SNN $34.97
- QGEN $107.74
- Revenue Growth
- SNN 5.48
- QGEN 0.62
- 52 Week Low
- SNN $23.65
- QGEN $39.03
- 52 Week High
- SNN $31.72
- QGEN $47.44
- Technical
- Relative Strength Index (RSI)
- SNN 34.52
- QGEN 54.59
- Support Level
- SNN $25.32
- QGEN $44.02
- Resistance Level
- SNN $25.70
- QGEN $46.08
- Average True Range (ATR)
- SNN 0.32
- QGEN 0.76
- MACD
- SNN -0.01
- QGEN -0.03
- Stochastic Oscillator
- SNN 5.02
- QGEN 41.98
About SNN Smith & Nephew SNATS Inc.
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound care solutions. Roughly 41% of the UK-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 29% of revenue is from the advanced wound therapy segment. Over half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
About QGEN Qiagen N.V.
Qiagen offers proprietary sample and assay technology to extract, purify, amplify, and interpret DNA, RNA, and proteins. The company's sales are split almost evenly between applications in life sciences and molecular diagnostics. Qiagen generates nearly 90% of its revenue from consumables with the balance coming from instrumentation and related services. The Americas account for the largest portion of the firm's revenue (52% of 2023 sales), followed by EMEA (32%), and the Asia-Pacific (16%).